CytoSorbents to Present at the Inaugural American Association of Physicians of Indian Origin (AAPI) World Health Congress
July 17, 2024 07:00 ET
|
CytoSorbents
CytoSorbents CEO Dr. Phillip Chan to highlight its innovative critical care and cardiac surgery blood purification therapy at AAPI Conference this weekend
U.S. Post-Acute Market Report 2024: Post-Acute Executives Prioritize Artificial Intelligence For Workforce Management, Labor Shortages And New Federal Staffing Mandate Strain Nursing Homes
July 16, 2024 11:27 ET
|
Research and Markets
Dublin, July 16, 2024 (GLOBE NEWSWIRE) -- The "The 2024 U.S. Post-Acute Market Report" report has been added to ResearchAndMarkets.com's offering. The U.S. post-acute market is expected to reach...
Physician-Patient Alliance for Health and Safety Grants CME Accreditation to Second Wave of 2024 World Sepsis Spotlight Courses
June 26, 2024 10:00 ET
|
The Physician-Patient Alliance for Health & Safety
Chicago, IL, June 26, 2024 (GLOBE NEWSWIRE) -- We are pleased to announce that the remaining 4 sessions from the World Sepsis Spotlight: Unmet Need in Sepsis Diagnosis and Treatment, hosted by...
AUROBAC THERAPEUTICS APPOINTS SCIENTIFIC ADVISORY BOARD
June 20, 2024 08:00 ET
|
AUROBAC THERAPEUTICS
The newly formed Scientific Advisory Board chaired by Dr. Marco Taglietti will provide technical and strategic guidance to support AUROBAC’s R&D strategy. Lyon (France), June 20, 2024 ...
Physician-Patient Alliance for Health and Safety Grants CME Accreditation to First Wave of 2024 World Sepsis Spotlight Courses
June 11, 2024 10:00 ET
|
The Physician-Patient Alliance for Health & Safety
Physician-Patient Alliance for Health & Safety accredits first 4 sessions from the World Sepsis Spotlight: Unmet Needs in Sepsis Diagnosis and Treatment.
AUROBAC THERAPEUTICS Presents its R&D Strategy & Pipeline and Announces New Development Program in Partnership with Boehringer Ingelheim
June 03, 2024 08:14 ET
|
AUROBAC THERAPEUTICS
AUROBAC THERAPEUTICS to advance ATX101 in septic shock, and multiple preclinical and discovery programs targeting Gram-negative pathogens. Lyon (France), June 3, 2024 AUROBAC THERAPEUTICS, a...
deepull appoints Didier Deltort to its Board of Directors
May 22, 2024 03:00 ET
|
DeepUll
deepull appoints Didier Deltort to its Board of Directors Barcelona, Spain – 22 May 2024 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen...
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024
April 25, 2024 03:00 ET
|
DeepUll
deepull unveils 1 hour, direct-from-blood multiplex PCR test for 95% of sepsis-causing pathogens at ESCMID 2024 UllCORE is designed to transform life-saving clinical decision making for sepsis...
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer
April 18, 2024 02:00 ET
|
DeepUll
deepull appoints Kimberle Chapin, MD, as Chief Medical Officer and Wade Stevenson as Chief Marketing and Sales Officer Kimberle Chapin brings significant expertise in microbiology and infectious...
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis
April 11, 2024 08:05 ET
|
Enlivex Therapeutics Ltd
Analysis of eligible1 patients from the sepsis Phase II study (NCT# NCT04612413) In accordance with the study protocol, the safety and efficacy topline analysis includes...